Literature DB >> 32988822

A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during Staphylococcus aureus Bone and Joint Infections.

Johan Courjon1,2, Margaux Garzaro3, Pierre-Marie Roger4, Raymond Ruimy2,5, Thibaud Lavrut6,7, Mikaël Chelli8, Jean-Luc Raynier8, David Chirio3,7, Elisa Demonchy3, Laura Cabane9, François Jehl10, Christophe Trojani7,8, Antoine Grillon10, Sylvain Goutelle11,12,13.   

Abstract

Intravenous administration of antibiotics is recommended during the early phase of methicillin-susceptible S. aureus (MSSA) bone and joint infection (BJI). We sought to compare the plasma concentrations of cloxacillin administered alternately by continuous and intermittent infusion (CI and ItI) in patients with MSSA BJI. In this prospective crossover trial, patients were randomly assigned to receive either 3 days of CI (two 75-mg/kg 12-h cloxacillin infusions per day) and then 3 days of ItI (four 37.5-mg/kg 1-h cloxacillin infusions per day) or vice versa. The drug concentration measurement was performed on day 3 of each type of administration at 1, 6, and 11 h and at 1, 2, 3, 4, and 6 h after the beginning of CI and ItI, respectively. We used the nonparametric algorithm NPAG to estimate population pharmacokinetic (PK) parameters. The final model was used to perform pharmacokinetic/pharmacodynamic (PK/PD) simulations and calculate the probabilities of target attainment (PTA) for several ItI and CI dosing regimens. We considered two PK/PD targets of time spent above the MIC for free cloxacillin concentrations (fT >MIC): 50 and 100%. Eighty-four concentrations from 11 patients were analyzed. A two-compartment model adequately described the data. ItI with q6h regimens and short 1-h infusions of 2,000 or 3,000 mg were associated with low PTA, even for the low target (50% fT >MIC) while 3-h infusions and continuous infusions (6 to 12 g/day) were associated with a PTA of >90% for an MIC up to 0.5 mg/liter. These results support the use of prolonged or continuous infusion of cloxacillin in patients with BJI.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureus; antibiotics; bone and joint infections; cloxacillin; continuous infusion; osteomyelitis; penicillin; pharmacodynamic; pharmacokinetics; population PK analysis; population pharmacokinetics

Year:  2020        PMID: 32988822      PMCID: PMC7674037          DOI: 10.1128/AAC.01562-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.

Authors:  Marta Ulldemolins; Jason A Roberts; Steven C Wallis; Jordi Rello; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2010-06-08       Impact factor: 5.790

2.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

3.  Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients.

Authors:  M C Verdier; O Tribut; P Tattevin; C Michelet; D Bentué-Ferrer
Journal:  J Chemother       Date:  2011-10       Impact factor: 1.714

4.  Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.

Authors:  S Weis; M Kesselmeier; J S Davis; A M Morris; S Lee; A Scherag; S Hagel; M W Pletz
Journal:  Clin Microbiol Infect       Date:  2019-03-27       Impact factor: 8.067

Review 5.  Metabolic response to injury and sepsis: changes in protein metabolism.

Authors:  G Biolo; G Toigo; B Ciocchi; R Situlin; F Iscra; A Gullo; G Guarnieri
Journal:  Nutrition       Date:  1997-09       Impact factor: 4.008

Review 6.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

7.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 8.  Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.

Authors:  Young R Lee; Pamela D Miller; Saeed K Alzghari; Delilah D Blanco; Jackson D Hager; Kailey S Kuntz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

9.  Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.

Authors:  Darrel W Hughes; Christopher R Frei; Pamela R Maxwell; Kay Green; Jan E Patterson; George E Crawford; James S Lewis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

10.  Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects.

Authors:  Mathilde Neuville; Najoua El-Helali; Eric Magalhaes; Aguila Radjou; Roland Smonig; Jean-François Soubirou; Guillaume Voiriot; Alban Le Monnier; Stéphane Ruckly; Lila Bouadma; Romain Sonneville; Jean-François Timsit; Bruno Mourvillier
Journal:  Ann Intensive Care       Date:  2017-03-22       Impact factor: 6.925

View more
  2 in total

Review 1.  Antibiotic Therapy for Prosthetic Joint Infections: An Overview.

Authors:  Benjamin Le Vavasseur; Valérie Zeller
Journal:  Antibiotics (Basel)       Date:  2022-04-05

Review 2.  Model-Informed Precision Dosing of Antibiotics in Osteoarticular Infections.

Authors:  Lingling Liu; Jin Wang; Huan Zhang; Mengli Chen; Yun Cai
Journal:  Infect Drug Resist       Date:  2022-01-11       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.